Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9.
View/ Open
Date
2016-08-01Author
Rye, CS
Chessum, NEA
Lamont, S
Pike, KG
Faulder, P
Demeritt, J
Kemmitt, P
Tucker, J
Zani, L
Cheeseman, MD
Isaac, R
Goodwin, L
Boros, J
Raynaud, F
Hayes, A
Henley, AT
de Billy, E
Lynch, CJ
Sharp, SY
Te Poele, R
Fee, LO
Foote, KM
Green, S
Workman, P
Jones, K
Type
Journal Article
Metadata
Show full item recordAbstract
Heat shock factor 1 (HSF1) is a transcription factor that plays key roles in cancer, including providing a mechanism for cell survival under proteotoxic stress. Therefore, inhibition of the HSF1-stress pathway represents an exciting new opportunity in cancer treatment. We employed an unbiased phenotypic screen to discover inhibitors of the HSF1-stress pathway. Using this approach we identified an initial hit (1) based on a 4,6-pyrimidine scaffold (2.00 μM). Optimisation of cellular SAR led to an inhibitor with improved potency (25, 15 nM) in the HSF1 phenotypic assay. The 4,6-pyrimidine 25 was also shown to have high potency against the CDK9 enzyme (3 nM).
Collections
Research team
Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
Medicinal Chemistry 3
Sarcoma and Melanoma Surgery
Language
eng
Date accepted
2016-06-07
License start date
2016-08
Citation
MedChemComm, 2016, 7 (8), pp. 1580 - 1586
Publisher
ROYAL SOC CHEMISTRY